Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Gynecologic 2Gastrointestinal 2Breast 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Classical hematology 1

Conditions

Advanced Solid Tumors 4Triple Negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Childhood Solid Tumors 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1Advanced Ovarian Cancer 1

Interventions

pembrolizumab 6Nivolumab 3tislelizumab 2budigalimab 2Ipilimumab 2Depsipeptides 2Decitabine 2venetoclax 1talazoparib 1spartalizumab 1sargramostim 1rovalpituzumab tesirine 1regorafenib 1poly ICLC 1iodixanol 1epacadostat 1entinostat 1durvalumab 1cemiplimab 1avelumab 1atezolizumab 1alvocidib 1Tomography, Optical Coherence 1Tissue Banks 1Tablets 1Radiosurgery 1Radiofrequency Ablation 1Paclitaxel 1Iohexol 1Interferon-gamma 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × talazoparib × Other solid neoplasm × Clear all
NCT02567396 2017-04-24

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Withdrawn
BreastGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡